Pharsight

Amneal patents expiration

1. Lyvispah patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11654124 AMNEAL Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
Jul, 2039

(15 years from now)

US10792262 AMNEAL Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
Jul, 2039

(15 years from now)

US11931328 AMNEAL Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
Jul, 2039

(15 years from now)

US11850225 AMNEAL Baclofen formulations and methods of minimizing patient exposure to metabolite variations
Sep, 2041

(17 years from now)

US11491125 AMNEAL Baclofen formulations and methods of minimizing patient exposure to metabolite variations
Sep, 2041

(17 years from now)

Drugs and Companies using BACLOFEN ingredient

Market Authorisation Date: 22 November, 2021

Treatment: Method for treating spasticity; Treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity

Dosage: GRANULES;ORAL

More Information on Dosage

LYVISPAH family patents

Family Patents

2. Tigecycline patents expiration

Can you believe TIGECYCLINE received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9855355 AMNEAL Method and device for plasma-treating hollow bodies
Apr, 2033

(8 years from now)

US9855335 AMNEAL Tigecycline composition for injection
Apr, 2033

(8 years from now)

Drugs and Companies using TIGECYCLINE ingredient

Market Authorisation Date: 02 August, 2018

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

TIGECYCLINE family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Zomig patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5466699 AMNEAL Indolyl compounds for treating migraine
Nov, 2012

(11 years ago)

US5466699

(Pediatric)

AMNEAL Indolyl compounds for treating migraine
May, 2013

(11 years ago)

US7220767 AMNEAL Pharmaceutical formulations containing zolmitriptan
Nov, 2020

(3 years ago)

US6750237 AMNEAL Pharmaceutical formulations containing zolmitriptan
Nov, 2020

(3 years ago)

US6750237

(Pediatric)

AMNEAL Pharmaceutical formulations containing zolmitriptan
May, 2021

(2 years ago)

US7220767

(Pediatric)

AMNEAL Pharmaceutical formulations containing zolmitriptan
May, 2021

(2 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jun 12, 2018

Drugs and Companies using ZOLMITRIPTAN ingredient

Market Authorisation Date: 16 September, 2013

Treatment: Acute treatment of migraine attacks with or without aura in adults

Dosage: SPRAY;NASAL

How can I launch a generic of ZOMIG before it's drug patent expiration?
More Information on Dosage

ZOMIG family patents

Family Patents